[Epidemiological and clinicopathological characteristics of prostate cancer in Hunan]

Zhonghua Nan Ke Xue. 2022 Sep;28(9):786-791.
[Article in Chinese]

Abstract

Objective: To investigate the epidemiological and clinicopathological characteristics of PCa and provide some strategies for the clinical prevention and treatment of the malignancy.

Methods: This study included 1 594 cases of pathologically diagnosed PCa after radical prostatectomy in Xiangya Hospital of Central South University from January 1, 2010 to December 31, 2020. We collected the basic information about the patients, their main complaints and clinicopathological results, and analyzed the epidemiological and clinicopathological data.

Results: The patients were aged from 28 to 93 years, and the number of PCa cases showed an overall upward trend from 2010 to 2020. Urinary system symptoms were most common (62.53%) as initial symptoms, followed by increased PSA (17.82%), PCa, prostate nodule, prostate mass (8.43%) and bone metastasis (2.94%) found at physical examinations, and the cases of PSA elevation among the clinic visitors increased year by year from 2010 to 2020. Gleason score 7 was found in a largest proportion of the PCa patients, and adenocarcinoma was the main pathological type (78.6%). Logistic regression analysis showed that high Gleason score, instead of age and expressions of Ki67, AR and ERG, was an independent risk factor for intraductal carcinoma.

Conclusion: The incidence of PCa shows an increasing trend, and is more common in those over 50 years old. PSA screening is gradually popularized in China. Intraductal carcinoma, as a major risk factor for aggressive PCa and poor prognosis of the malignancy, is significantly correlated with high Gleason scores.

Keywords: prostate cancer; epidemiology; pathological features; Gleason score; intraductal carcinoma.

Publication types

  • English Abstract

MeSH terms

  • Carcinoma, Intraductal, Noninfiltrating* / surgery
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatectomy / methods
  • Prostatic Neoplasms* / pathology

Substances

  • Prostate-Specific Antigen